These novel anthraquinone-derived compounds inhibit tNOX-NAD+-SIRT1 axis to induce apoptosis, highlighting the value of tNOX as a possible therapeutic target and implying future clinical use of these compounds in cancer treatment without considering p53 expression. The gene discussed is ENOX2; the disease is cancer.